March 19, 2019 Acad, Gov/Utilities

FDA approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer

Basel, 19 March 2019 FDA approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved for the initial treatment of extensive-stage small cell lung cancer (ES-SCLC) First new initial treatment... Read more

March 14, 2019 Acad, Gov/Utilities Bio/Pharma/CRO PR/Corporate

BD Receives U.S. FDA Approval for First Venous Stent to Treat Iliofemoral Venous Occlusive Disease

FRANKLIN LAKES, N.J., March 14, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration has granted premarket approval for the Venovo™ venous stent, the first stent indicated to treat iliofemoral venous occlusive disease, which is obstructed or narrowed blood flow specific to... Read more

March 11, 2019 Acad, Gov/Utilities Licensing, IP, and Legal

FDA grants Roche’s Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer

Basel, 11 March 2019 FDA grants Roche’s Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer This Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer Triple-negative breast cancer is an aggressive disease, with high unmet medical need Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced... Read more

March 7, 2019 Acad, Gov/Utilities Product Launch

Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions

Basel, 07 March 2019 Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions Application is being reviewed under FDA’s Real-Time Oncology Review pilot programme Combination was granted Breakthrough Therapy Designation, the fifth for Venclexta Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced... Read more

March 7, 2019 Acad, Gov/Utilities Lab Top-10

MilliporeSigma Brings Science Education to Students Across North America with Curiosity Cube® Mobile Science Lab

Burlington, Massachusetts, March 7, 2019 — MilliporeSigma is igniting student interest in science with its third annual Curiosity Cube® mobile science lab tour. “We’ve seen firsthand how the interactive learning that takes place inside the Curiosity Cube® can spark curiosity crucial for developing a passion for science,” said Udit Batra, CEO, MilliporeSigma. “We will continue to... Read more

March 6, 2019 Acad, Gov/Utilities Lab Top-10 Licensing, IP, and Legal M&A, Partnerships

Agilent and Imperial College London Strengthen Partnership

Agilent and Imperial College London Strengthen Partnership Agilent Measurement Suite at Imperial to boost research in molecular sciences SANTA CLARA, Calif., March 6, 2019 Agilent Technologies Inc. (NYSE: A) and Imperial College London have announced that, as part of its ongoing collaboration, several state-of-the-art analytical instruments have been installed into the college’s Molecular Sciences Research... Read more

March 4, 2019 Acad, Gov/Utilities M&A, Partnerships

MTS Helps University Protect Architectural Heritage In Latin America

EDEN PRAIRIE, Minn., March 4, 2019 /PRNewswire/ — MTS Systems Corporation (NASDAQ: MTSC), a leading global supplier of high-performance test systems, motion simulators and sensors, today announced a research collaboration with the Sismo Lab at Universidad Mariano Gálvez in Guatemala City, Guatemala to create seismic simulation solutions that will help predict and minimize earthquake damage to... Read more

February 28, 2019 Acad, Gov/Utilities

FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers

Basel, 28 February 2019 FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment of certain people with HER2-positive early breast... Read more

February 19, 2019 Acad, Gov/Utilities

FDA grants Priority Review to Roche’s personalised medicine entrectinib

Basel, 19 February 2019 FDA grants Priority Review to Roche’s personalised medicine entrectinib Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of adult and paediatric patients with neurotrophic tropomyosin receptor... Read more

February 19, 2019 Acad, Gov/Utilities

FDA grants priority review to Roche’s polatuzumab vedotin in previously treated aggressive lymphoma

Basel, 19 February 2019 FDA grants priority review to Roche’s polatuzumab vedotin in previously treated aggressive lymphoma Diffuse large B-cell lymphoma is an aggressive type of blood cancer that typically becomes harder to treat each time it returns Polatuzumab vedotin has shown significant potential to improve outcomes in people living with this disease Roche (SIX:... Read more